Organic compounds -- part of the class 532-570 series – Organic compounds – Chalcogen in the nitrogen containing substituent
Reexamination Certificate
2004-08-13
2008-09-30
Shiao, Rei-Tsang (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Chalcogen in the nitrogen containing substituent
C544S145000, C544S147000
Reexamination Certificate
active
07429660
ABSTRACT:
A compound of formula I:and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein: R1and R2together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; and RN1is selected from hydrogen, an optionally substituted C1-7alkyl group, an optionally substituted C3-20heterocyclyl group, an optionally substituted C5-20aryl group, an acyl group, an ester group and an amido group, and its use as a pharmaceutical.
REFERENCES:
patent: 4954518 (1990-09-01), Takano et al.
patent: 5252735 (1993-10-01), Morris
patent: 5284856 (1994-02-01), Naik et al.
patent: 5302613 (1994-04-01), Morris
patent: 5703075 (1997-12-01), Gammill et al.
patent: 5733920 (1998-03-01), Mansuri et al.
patent: 5922755 (1999-07-01), Tanaka et al.
patent: 6348311 (2002-02-01), Kastan et al.
patent: 6387640 (2002-05-01), Kastan et al.
patent: 7049313 (2006-05-01), Smith et al.
patent: 2004/0002492 (2004-01-01), Murray Smith et al.
patent: 2004/0023968 (2004-02-01), Martin et al.
patent: 2004/0192687 (2004-09-01), Martin et al.
patent: 2006/0106025 (2006-05-01), Smith et al.
patent: 2006/0178361 (2006-08-01), Hummersone et al.
patent: 0610519 (1994-08-01), None
patent: 0635268 (1995-01-01), None
patent: 0640339 (1995-03-01), None
patent: 0641566 (1995-03-01), None
patent: 0648492 (1995-04-01), None
patent: 0658343 (1995-06-01), None
patent: 1303724 (1973-01-01), None
patent: 2302021 (1997-01-01), None
patent: 03215-423 (1990-01-01), None
patent: WO 90/06921 (1990-06-01), None
patent: WO 91/19707 (1991-12-01), None
patent: WO 92/00290 (1992-01-01), None
patent: WO 95/29673 (1995-11-01), None
patent: WO 96/01108 (1996-01-01), None
patent: WO 97/15658 (1997-05-01), None
patent: WO 97/18323 (1997-05-01), None
patent: WO 98/55602 (1998-12-01), None
patent: WO 98/56391 (1998-12-01), None
patent: WO 99/47494 (1999-09-01), None
patent: WO 01/53266 (2001-07-01), None
patent: WO 02/20500 (2002-03-01), None
patent: WO 02/056912 (2002-07-01), None
patent: WO 03/024949 (2003-03-01), None
patent: WO 03/093261 (2003-04-01), None
patent: WO 03/034997 (2003-05-01), None
patent: WO 03/035618 (2003-05-01), None
patent: WO 03/070726 (2003-08-01), None
patent: 2006032869 (2006-03-01), None
Ismail, I.H. et al., “SU11752 inhibits the DNA-dependent protein kinase and DNA double-strand break repair resulting in ionizing radiation sensitization,” Oncogene (2004) 23:873-883.
Kashishian, A. et al., “DNA-dependent protein kinase inhibitors as drug candidates for the treatment of cancer,” Mol. Cancer Ther. (2003) 2:1257-1264.
Lau et al., “Suppression of HIV-I infection by a small molecule inhibitor of the ATM kinase,” Nature Cell Biology (2002) 7:493-500.
Muller, C. et al., “DNA-dependent protein kinase activity correlates with clinical and in vitro sensitivity of chronic lymphocytic leukemia lymphocytes to nitrogen mustards,” Blood (1998) 92:2213-2219.
Sirzen, F. et al., “DNA-dependent protein kinase content and activity in lung carcinoma cell lines: Correlation with intrinsic radiosensitivity,” Eur. J. Cancer (1999) 35:111-116.
Abraham, Robert T., “Cell cycle checkpoint signaling through the ATM and ATR kinases,”Genes&Dev., 15: 2177-2196 (2001).
Archer, S. et al., “Ring-Hydroxylated Analogues of Lucanthone as Antitumor Agents,”J. Med. Chem., 25, 220-227 (1982).
Banin, S., et al., “Enhanced Phosphorylation of p53 by ATM in Response to DNA Damage,”Science, 281:1674-1677 (1998).
Bantick, J.R., et al., “Synthesis of 2-aminochromones,”J. Heterocyclic Chem., 1981, vol. 18, pp. 679-684.
Berge, Stephen M., et al., “Review article,”J. Pharm. Sci., 66:1, pp. 1-19 (1977).
Bettoni, et al., “Synthesis and absolute configuration of substituted morpholines,”Tetrahedron, 1980, vol. 36, pp. 409-415.
Boyd, J., et al., “The chemistry of the ‘insoluble red’ woods,”J. Chem. Soc., 1948, pp. 174-176.
Brown, P.O., “Integration of retroviral DNA,”Curr. Top Microbiol. Immunol., 157:19-48 (1990).
Buon, C., et al., “Synthesis of 3-substituted and 2,3-disubstituted-4H-1,4- Benzoxazines,”Tetrahedron, 2000, vol. 56, pp. 605-614.
Chiosis G, et al. “LY294002-geldanamycin heterodiamers as selective inhibitors of the PI3K and PI3k-related family”, Bioorganic & Medicinal Chemistry Letters, vol. 11, No. 7, Apr. 9, 2001 pp. 909-913, XP004232522.
Daniel, R., et al., “A role for DNA-PK in retroviral DNA integration,”Science, 1999, vol. 284, pp. 644-647.
Daniel, Rene, et al., “Wortmannin Potentiates Integrase-Mediated Killing of Lymphocytes and Reduces the Efficiency of Stable Transduction by Retroviruses,”Mol. Cell Biol., 21(4): 1164-1172 (2001).
Datta, A., et al., “Reformatsky reaction on aroylketene S, N-acetals: a facile route to 4-amino-6-aryl-2H-pyran-2-ones,”Synthesis, 1988, vol. 3, pp. 248-250.
Di Braccio, M., et al., “1,2-fused pyrimidines VII,”Eur. J. Med., Chem., 1995, vol. 30, No. 1, pp. 27-38.
Di Braccio, M., et al., “Pyran derivatives XIX. (Dialkylamino) substituted 1-benzopyranones and naphthopyranoes with platelet antiaggregating activity,”Farmaco, 1995, vol. 50, No. 10, pp. 703-711.
Durocher, Daniel, and Jackson, Stephen P., “DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme?,”Curr. Opin. Cell Biol., 13:225-231 (2001).
Ermili, A., et al., “Chemical and pharamacological research on pyran derivatives,” Enclosed:Chemical Abstracts, 1977, vol. 87, No. 15, p. 588 (XP-002218602). 117750g.
Gell, D., et al., “Mapping of protein-protein interactions within the DNA-dependent protein kinase complex,”Nucleic Acid Res., 1999, vol. 27, No. 17, pp. 3494-3502.
Giroux, A., et al., “One Pot Biaryl Synthesis via in situ Boronate Formation,”Tet. Lett., 38:22, 3841-3844 (1997).
Goytisolo, et al., “The absence of DNA-dependent protein kinase catalytic subunit in mice results in anaphase bridges and in increased telomeric fusions with normal telomere length and G-strand overhang,”Mol. Cell. Biol., 2001, vol. 21, No. 11, pp. 3642-3651.
Green, T. and Wuts, P., ed., “Protective Groups in Organic Synthesis,” Wiley (1999) (book not provided).
Griffin, et al., “Selective Benzopyranone and Pyrimido [2,1-a]isoquinolin-4-one Inhibitors of DNA-Dependent Protein Kinase: Synthesis, Structure—Activity Studies, and Radiosensitization of a Humn Tumor Cell Line in Vitro”, J. Med. Chem., 2005, 48, 569-585.
Hartley, K. O., et al., “DNA-dependent protein kinase catalytic subunit: a relative of phosphatidylinositol 3-kinase and the ataxia telengiectasia gene product,”Cell, 1995, vol. 82, pp. 849-856.
Haselhorst, Dörte, et al., “Development of cell lines stably expressing human immunodeficiency virus type 1 proteins for studies in encapsidation and gene transfer,”J. Gen. Virol., 79: 231-237 (1998).
Herzog, Karl-Heinz et al., “Requirement for Atm in Ionizing Radiation-Induced Cell Death in the Developing Central Nervous System,”Science, 280: 1089-1091 (1998).
Hickson, Ian, et al, Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase, ATM, Cancer Research 64, Dec. 15, 2004, 9152-9159.
Hollick, J J, et al., “2,6-Disubstituted pyran-4-one and thiopyran-4-one inhibitors of DNA-dependent protein kinase” Bioorganic and Medicinal Chemistry Letters, vol. 13, No. 18, Sep. 15, 2003 pp. 3083-3086, XP002303369.
Ishiyama, T. et al., “Synthesis of Arylboronatesviathe Palladium(0)-catalyzed Cross-Coupling Reaction of Tetra(alkoxo) diborons with Aryl Triflates,”Tett. Lett., 38:19, 3447-3450 (1997).
Izzard, R.A., et al., “Competitive & noncompetitive inhibition of the DNA-dependent protein kinase,”Cancer Research, 1999, vol. 59, No. 11, pp. 2581-2586.
Barr Martin Niall Morrison
Cockcroft Xiao-Ling Fan
Griffin Roger John
Hummersone Marc Geoffrey
Matthews Ian Timothy Williams
Kudos Pharmaceuticals Limited
Michael & Best & Friedrich LLP
LandOfFree
ATM inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with ATM inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ATM inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3977031